Allergan Pharmaceuticals International

Company snapshot

Allergan Pharmaceuticals International is a pharma organization headquartered in Dublin, IE. Primary therapeutic focus areas include Glaucoma, Macular Edema, Macular Degeneration, Dry Eye Syndromes, Choroid Neovascularization. NovaPharmaNews links 13 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (8), phase 2 (5).

• 13 active pipeline program(s) linked via ClinicalTrials.gov.
• 25 US patent(s) indexed to this assignee profile.
• 13 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Allergan Pharmaceuticals International. Not investment advice.

• approval Jun 3, 2026

  AbbVie Plans Layoffs: Implications for the Pharma Industry

• approval Jun 8, 2026

  Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses

• Peer + 0 momentum

  AEON Biopharma

  TA overlap score 21.8

Recent activity

Latest pipeline, patent, and corporate events for Allergan Pharmaceuticals International.

1. Jun 8, 2026 Clinical update

   Placebo — Phase 3

2. Jun 8, 2026 Clinical update

   Gatifloxacin 0.3% ophthalmic solution — Phase 2

3. Jun 8, 2026 Clinical update

   Brimo PS DDS® — Phase 2

4. Jun 8, 2026 Clinical update

   botulinum toxin Type A — Phase 3

5. Jun 8, 2026 Clinical update

   botulinum toxin type A — Phase 2

View all clinical trial activity →

• What is Allergan Pharmaceuticals International?

  Allergan Pharmaceuticals International is a pharma organization headquartered in Dublin, IE. Primary therapeutic focus areas include Glaucoma, Macular Edema, Macular Degeneration, Dry Eye Syndromes, Choroid Neovascularization. NovaPharmaNews links 13 clinical program(s), 0 drug p

• Is Allergan Pharmaceuticals International publicly traded?

  Allergan Pharmaceuticals International appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Allergan Pharmaceuticals International develop or market?

  We link 15 drug profile(s) where Allergan Pharmaceuticals International is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/allergan-pharmaceuticals-international-limited#company-drugs.

• What are the latest developments for Allergan Pharmaceuticals International?

  In the last 12 months our linked public records show 13 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Allergan Pharmaceuticals International focus on?

  Allergan Pharmaceuticals International focuses on Glaucoma, Macular Edema, Macular Degeneration based on our analysis of their pipeline programs and drug development activities.